Search results
Results from the WOW.Com Content Network
Drug Manufacturer Indication Ivacaftor [1] Vertex Pharmaceuticals: cystic fibrosis with CFTR mutation Ofatumumab [1] Novartis Pharmaceuticals: chronic lymphocytic leukemia: Ceritinib [1] Novartis Pharmaceuticals: ALK-positive metastatic non-small cell lung cancer: Idelalisib [1] Gilead Sciences: relapsed chronic lymphocytic leukemia: Ibrutinib ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Following is a list of antipsychotics, sorted by class. Antipsychotics. Antipsychotics by class Generic name Brand names Chemical class ATC code
This is a list of investigational agitation drugs, or drugs that are currently under development for clinical use in the treatment of agitation, for instance in people with dementia or autism, but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. [2] For CLL it is a preferred treatment. [3] It is given by mouth. [3] Common side effects include bone marrow suppression. [3]
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs , ranked by sales.
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion. [21]: 3, 7–8 Competition as well as potential for combination is expected from other drugs such as ibrutinib and idelalisib, both of which were also approved in 2014 to treat CLL. [21]: 7–8 [22]